A

AC Camargo Cancer Center | International Research Center (CIPE)

Research site

(Unclaimed)

Location

R. Tagua, 440, Liberdade, Sao Paulo, Sao Paulo, Brazil

Site insights

Top conditions

Top treatments

Gemcitabine

TAR-200

Nivolumab

Bemarituzumab

Everolimus

Cisplatin

Pembrolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 7 total trials

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors.The study aims ar...

Active, not recruiting

Advanced or Metastatic Solid Tumors

Drug: Pembrolizumab

Drug: TAK-981

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting

Urinary Bladder Neoplasms

Drug: Cisplatin

Radiation: Hypo-fractioned radiation therapy

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (FORTITUDE-102)

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting

Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Other: Placebo

Drug: Nivolumab